An interplay of microglia and matrix metalloproteinase MMP9 under hypoxic stress regulates the opticin expression in

Satish Patnaik1,2, Meenakshi Rai1, Subhadra Jalali3

  • 1Prof. Brien Holden Eye Research Centre, LV Prasad Eye Institute, Hyderabad, India.

Scientific Reports
|April 3, 2021
PubMed

Insights

Matrix metalloproteinases (MMPs) in premature infants correlate with retinopathy of prematurity (ROP) severity. Inhibiting MMPs in microglia under hypoxia restored opticin levels, suggesting MMPs as a therapeutic target for ROP.

Area of Science:

  • Ophthalmology
  • Neonatology
  • Molecular Biology

Background:

  • Retinopathy of prematurity (ROP) involves inflammation and an imbalance of angiogenic and anti-angiogenic factors.
  • Increased matrix metalloproteinase (MMP) activity in ROP eyes was previously observed.

Purpose of the Study:

  • To investigate the correlation between tear MMP levels and ROP severity.
  • To elucidate the role of microglia-secreted MMPs in regulating opticin levels in ROP.

Main Methods:

  • Correlation analysis of tear MMP levels with ROP disease severity in premature infants.
  • In vitro study using human microglia cell line (CHME3) exposed to hypoxia.
  • Assessing the effect of MMP inhibition (doxycycline, EDTA) on opticin and other signaling molecules under hypoxia.

Main Results:

  • Tear MMP levels in premature infants strongly correlated with ROP severity.
  • Hypoxia induced increased MMP9 and VEGF expression while significantly reducing opticin in microglia.
  • MMP inhibition restored opticin levels and modulated other signaling pathways in hypoxic microglia.

Conclusions:

  • Increased MMP activity under hypoxia regulates opticin expression in the context of ROP.
  • MMPs represent a potential therapeutic target for managing retinopathy of prematurity.